Martinez, CA – According to filings with the U.S. Securities and Exchange Commission, ExThera Medical is raising $20,572,151.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Ward played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ExThera Medical

ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph 100 Microbind Affinity Blood Filter for removing a broad range of harmful substances from the bloodstream of patients. Seraph can be used in hospitals, clinics, or field hospitals to address infections caused by battlefield wounds or pandemics. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections. With a growing body of outcome and health economic evidence from independent clinical studies, participation in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US and EU, the company is well-positioned to serve healthcare professionals and patients alike. The Seraph 100 is CE marked and commercially available in the EU, and has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.

To learn more about ExThera Medical, visit http://www.extheramedical.com/

Contact:
Robert Ward, Chief Executive Officer
925-839-2060
robert.ward@extheramedical.com
https://www.linkedin.com/in/robert-ward-12134449/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved